Modification of pre-mRNA splicing by antisense oligonucleotides

Acta Biochimica Polonica

Volumn 44, Issue 2, 1997, Pages 231-238

  Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Gene expression; Gene therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; RNA PRECURSOR;

ANIMAL; DRUG EFFECT; GENE EXPRESSION; GENETICS; HELA CELL; HUMAN; METABOLISM; REVIEW; RNA SPLICING;

ANIMALS; GENE EXPRESSION; HELA CELLS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER;

EID: 0031304382     PISSN: 0001527X     EISSN: None     Source Type: Journal    
DOI: 10.18388/abp.1997_4418     Document Type: Review

References (36)

1. Zhang, R., Ya, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M.S., Jiang, Z., Temsamani, J. & Martin, R.R. (1995) In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Clin. Pharm. Ther. 58, 44-53.
2. Bishop, M.R., Iversen, P.L., Bayever, E., Shar, J.G., Greiner, T.C., Copple, B.L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., Armitage, J.O. & Kessinger, A. (1995) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320-1326.
3. Agrawal, S. (1996) Antisense oligonucleotides: Towards clinical trials. Trends Biotech. 14, 376-378.
4. Jonkinson, J.L. & Stein, C.A. (1996) Antisense oligonucleotides as clinical therapeutic agents. Cancer Invest. 14, 64-65.
5. Crooke, S.T. & Lebleu, B. (eds) (1993) Antisense Research and Applications. CRC Press, Boca Raton.
6. Pasternak, G.W. & Standifer, K.M. (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: Correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16, 344-350.
7. Niggli, E., Schwaller, B. & Lipp, P. (1996) Antisense oligodeoxynucleotides directed against the Na-Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Ann. NY Acad. Sci. 779, 93-102.
8. Ramchandani, S., MacLeod, R.A., Pinard, M., von Hoffe, E. & Szyf, M. (1997) Inhibition of tumorigenesis by a cytosine-DNA, methyl-transferase, antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 94, 684-689.
9. Sharma, H.W. & Narayanan, R. (1995) The therapeutic potential of antisense oligonucleotides. BioEssays 17, 1055-1063.
10. Wagner, R.W. (1995) The state of the art in antisense research. Nature Med. 1, 1116-1118.
11. Crooke, S.T. & Bennett, C.F. (1996) Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharm. Tox. 36, 107-129.
12. Dominski, Z. & Kole, R. (1993) Restoration of correct splicing in thalasssemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 90, 8673-8677.
13. Sierakowska, H., Sambade, M.J., Agrawal, S. & Kole, R. (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A. 93, 12840-12844.
14. Moore, M.J., Query, C.C. & Sharp, P.A. (1993) Splicing of precursors to mRNA by the spliceosome; in RNA World (Gesteland, R.F. & Atkins, J.F., eds.) pp. 303-358, Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
15. Horowitz, D.S. & Krainer, A.R. (1994) Mechanisms for selecting 5′ splice sites in mammalian pre-mRNA splicing. Trends Genetics 10, 100-106.
16. Black, D.L. (1995) Finding splice sites within a wilderness of RNA. RNA 1, 763-771.
17. Reed, R. (1996) Initial splice-site recognition and pairing during pre-mRNA splicing. Curr. Opinion Gen. & Dev. 6, 215-220.
18. McKeown, M. (1990) Regulation of alternative splicing. Genetic Engineering 12, 139-181.
19. Hodges, D. & Bernstein, S.I. (1994) Genetic and biochemical analysis of alternative RNA splicing. Adv. Genetics 31, 207-281.
20. Krawczak, M., Reiss, J. & Cooper, D.N. (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences. Hum. Genet. 90, 41-54.
21. Dominski, Z. & Kole, R. (1992) Cooperation of pre-mRNA sequence elements in splice site selection. Mol. Cell. Biol. 12, 2108-2114.
22. Mayeda, A., Hayase, Y., Inoue, H., Ohtsuka, E. & Oshima, Y. (1990) Surveying cis-acting sequences of pre-mRNA by adding antisence 2′-O-methyloligoribonucleotides to a splicing reaction. J. Biochem. (Tokyo) 108, 399-405.
23. Schwartz, E. & Benz, E.J. (1995) The thalassemia syndrome; in Hematology, Basic Principles and Practice (Hoffman, R., Benz, E.J., Jr., Shattil, S.J., Furie, B., Cohen, H.J. & Silberstein, L.E., eds.) pp. 586-610, Churchill Livingstone, New York.
24. Weatherall, D.J. (1994) The thalassemias; in The Molecular Basis of Blood Diseases (Stamatoyannopoulos, G., Nienhuis, A.W., Majerus, P.W. & Varmus, H., eds.) pp. 157-205, W.B. Saunders & Co., Philadelphia.
25. Sproat, B.S. & Lamond, A.I. (1993) 2′-O-alkyloligoribonucleotides; in Antisense Research and Applications (Crooke, S.T. & Lebleu, B., eds.) pp. 351-363, CRC Press, Boca Raton.
26. Furdon, P.F., Dominski, Z. & Kole, R. (1989) RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17, 9193-9204.
27. Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R.B., Habus, I., Jiang, Z., Iyer, R.P., Yu, D. & Agrawal, S. (1995) In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharm. 50, 545-556.
28. Reed, R. & Maniatis, T. (1985) Intron sequences involved in lariat formation during pre-mRNA splicing. Cell 41, 95-105.
29. Zhuang, Y. & Weiner, A.M. (1989) A compensatory base change in human U2 snRNA can suppress a branch site mutation. Genes Dev. 3, 1545-1552.
30. Dominski, Z. & Kole, R. (1994) Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol. Cell. Biol. 14, 7445-7454.
31. Bennett, C.F., Chiang, M.-Y., Chan, H., Shoemaker, J.E.E. & Mirabelli, C.K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharm. 41, 1023-1033.
32. Lewis, J.G., Lin, K.Y., Kothavale, A., Flanagan, W.M., Matteucci, M.D., DePrince, R.B., Mook, R.A, Jr., Hendren, R.W. & Wagner, R.W. (1996) A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. U.S.A. 93, 3176-3181.
33. Gewirtz, A.M., Stein, C.A. & Glazer, P.M. (1996) Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. U.S.A. 93, 3161-3163.
34. Hawley-Nelson, P., Ciccarone, V., Gebeyehu, G., Jessee, J. & Feigner, P.L. (1993) Lipofectamine reagent: A new, higher efficiency polycationic liposome transfection reagent. Focus 15, 73-79.
35. Chun, J.D., Lee, N., Kobayashi, R.H., Chaffee, S., Hershfield, M.S. & Stiehm, E.R. (1993) Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Ann. Allerg. 70, 462-466.
36. Hirschhorn, R., Yang, D.R., Insel, R.A. & Ballow, M. (1993) Severe combined immunodeficiency of reduced severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro). Cell. Immun. 152, 383-393.